Winship investigators will present their research in poster sessions and special sessions at the 2018 American Association for Cancer Research (AACR) Annual Meeting, April 14–18, in Chicago.
Suresh Ramalingam, Winship deputy director and director of the Winship Lung Cancer Program, is a featured speaker in the plenary session on April 16 titled "Immunotherapy Combinations: The New Frontier in Lung Cancer." As lead author, Ramalingam will present the multi-institutional study "Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568."
"My presentation describes the results of a large trial that studied tumor mutation burden as a predictive biomarker for immune checkpoint inhibition in patients with advanced stage non-small cell lung cancer," said Ramalingam. "The results provide support to using this novel biomarker to select patients for therapy."
Winship radiation oncologist David Yu will moderate a Working Group Session on April 17, titled "Utilizing Molecular Signatures to Inform Clinical Outcome Predictions in Radiation Response." Yu says the session will explore the use of various molecular signatures for patient population identification and stratification: "Emphasis will be placed on how genomic, proteomic, and radiomic signatures may best predict radiation response, therapeutic resistance, and clinical outcome."
The theme of this year's annual meeting is Driving Innovative Cancer Science to Patient Care, reflecting developments in using big data to accelerate progress in cancer research and clinical care. The conference will highlight research on diagnosing cancer at an earlier stage; expanding the use of genomic data for precision medicine; and concentrating efforts to eliminate persistent disparities in cancer outcomes.
Visit the AACR Annual Meeting website for a complete list of abstracts.